Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary

Abstract

Importance of the field: Epithelial ovarian cancer (EOC) is the leading cause of death from gynecological malignancies in Western countries. Among the four major histological subtypes of EOC, clear cell carcinoma (CCC) of the ovary is highly resistant to platinum-based chemotherapy and is consequently associated with poor patient prognosis in advanced stages.

Areas covered in this review: An overview of the clinical characteristics of ovarian CCC; the role of annexin family proteins in tumor development and progression; the role of annexin A4 in enhancing cellular drug resistance; recent studies linking annexin A4 overexpression to chemoresistance in tumors of ovarian CCC.

What the reader will gain: Insight into the emerging role for annexin A4 in enhancing chemoresistance in ovarian CCC.

Take home message: Annexin A4 enhances cancer cell chemoresistance and is overexpressed in tumors of patients with ovarian CCC. Targeting of annexin A4 may represent a future strategy to counteract resistance to chemotherapy in ovarian CCC.

Keywords::

• annexin A4
• chemoresistance
• clear cell carcinoma of the ovary
• molecular targeted therapy

Notes

This box summarizes key points contained in the article.